Synaptogenix EBITDA 2020-2025 | TAOX
Synaptogenix ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Synaptogenix Annual EBITDA
(Millions of US $) |
| 2024 |
$-7 |
| 2023 |
$-8 |
| 2022 |
$-16 |
| 2021 |
$-13 |
| 2020 |
$-11 |
| 2019 |
$-16 |
Synaptogenix Quarterly EBITDA
(Millions of US $) |
| 2025-03-31 |
$-1 |
| 2024-12-31 |
$-2 |
| 2024-09-30 |
$-1 |
| 2024-06-30 |
$-2 |
| 2024-03-31 |
$-2 |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-1 |
| 2023-06-30 |
$-2 |
| 2023-03-31 |
$-3 |
| 2022-12-31 |
$-6 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-4 |
| 2022-03-31 |
$-3 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-3 |
| 2021-06-30 |
$-2 |
| 2021-03-31 |
$-3 |
| 2020-12-31 |
|
| 2020-09-30 |
$-3 |
| 2020-06-30 |
$-3 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.012B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
